OptiBiotix Health signs distribution agreement to help it grow

OptiBiotix Health has signed an exclusive distribution agreement with Shandong Longlive Biotechnology Co for the distribution of Longlive’s xylooligosaccharide prebiotic into the nutrition markets in Europe and Africa. The product will be branded OptiXOS.

In a statement OptiBiotix said: “Longlive is one of the global technology and market leaders in the novel prebiotic XOS. The company has a core capability in corn and corncob processing into various food ingredients such as starch, polyols, sugar replacers, monosaccharides and prebiotic fibres.

It added: “XOS is a prebiotic fibre with unique characteristics and benefits compared to other prebiotic fibres commercially available in Europe.

"Longlive has been successful in obtaining key regulatory approvals for XOS in the North American market (FDA GRAS and New Dietary Ingredient, Health Canada) and in 2018 obtained EFSA Novel Food approval opening up the European market.”

René Kamminga, CEO of OptiBiotix Limited, commented: “XOS is an important addition to OptiBiotix’s technology portfolio. It is a building block that will increase our importance in microbiome modulation and act as leverage for our more advanced science based prebiotic solutions in the food and beverage and supplement industry in Europe and Africa.

"The agreement with Longlive is another step for Optibiotix on its path to in-license or acquire unique technologies to broaden its product portfolio and reinforce our role as leaders in the microbiome field. We look forward to working with the team at Longlive to make this link-up into a significant contributor to our mutual business growth ambitions.”